Next Article in Journal
Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876
Next Article in Special Issue
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
Previous Article in Journal
Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge
Previous Article in Special Issue
Optimising Cancer Vaccine Design in Sarcoma
Open AccessArticle

Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model

Hudson Institute of Medical Research, Clayton 3168, Australia
Department of Molecular and Translational Sciences, Monash University, Clayton 3168, Australia
Department of Immunology and Pathology, Monash University, Clayton 3168, Australia
School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia
Centenary Institute, The University of Sydney, Sydney 2006, Australia
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
Robinson Institute, University of Adelaide, Adelaide 5000, Australia
Bruker Biosciences Pty Ltd., Preston 3072, Australia
Authors to whom correspondence should be addressed.
Cancers 2019, 11(1), 32;
Received: 26 November 2018 / Revised: 21 December 2018 / Accepted: 23 December 2018 / Published: 31 December 2018
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Ovarian cancers (OCs) are the most lethal gynaecological malignancy, with high levels of relapse and acquired chemo-resistance. Whilst the tumour–immune nexus controls both cancer progression and regression, the lack of an appropriate system to accurately model tumour stage and immune status has hampered the validation of clinically relevant immunotherapies and therapeutic vaccines to date. To address this need, we stably integrated the near-infrared phytochrome iRFP720 at the ROSA26 genomic locus of ID8 mouse OC cells. Intrabursal ovarian implantation into C57BL/6 mice, followed by regular, non-invasive fluorescence imaging, permitted the direct visualization of tumour mass and distribution over the course of progression. Four distinct phases of tumour growth and dissemination were detectable over time that closely mimicked clinical OC progression. Progression-related changes in immune cells also paralleled typical immune profiles observed in human OCs. Specifically, we observed changes in both the CD8+ T cell effector (Teff):regulatory (Treg) ratio, as well as the dendritic cell (DC)-to-myeloid derived suppressor cell (MDSC) ratio over time across multiple immune cell compartments and in peritoneal ascites. Importantly, iRFP720 expression had no detectible influence over immune profiles. This new model permits non-invasive, longitudinal tumour monitoring whilst preserving host–tumour immune interactions, and allows for the pre-clinical assessment of immune profiles throughout disease progression as well as the direct visualization of therapeutic responses. This simple fluorescence-based approach provides a useful new tool for the validation of novel immuno-therapeutics against OC. View Full-Text
Keywords: iRFP; iRFP720; ovarian cancer; ID8; syngeneic; immune; T cell; tumour iRFP; iRFP720; ovarian cancer; ID8; syngeneic; immune; T cell; tumour
Show Figures

Figure 1

MDPI and ACS Style

Wilson, A.L.; Wilson, K.L.; Bilandzic, M.; Moffitt, L.R.; Makanji, M.; Gorrell, M.D.; Oehler, M.K.; Rainczuk, A.; Stephens, A.N.; Plebanski, M. Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. Cancers 2019, 11, 32.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop